13:53:29 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-29 X-dag ordinarie utdelning POLAR 0.00 SEK
2024-05-28 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-09-08 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma 2023
2023-05-05 X-dag ordinarie utdelning POLAR 0.00 SEK
2023-03-13 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 X-dag ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 X-dag ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 X-dag ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 X-dag ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2024-06-13 08:21:00

The medical technology company PolarCool AB (publ.) has received approval from the Australian Register of Therapeutic Goods (TGA) for the PolarCap® System. The approval enables the PolarCap® System to be sold and distributed in Australia by an Australian-based distributor.

PolarCool develops the product PolarCap®, which alleviates the effects of concussions. The primary customers are sports clubs and facilities in ice hockey, rugby, football, and handball, but also other sports with an increased risk of concussion.

The TGA approval includes a certificate for both the SmallCool unit and the HeadCap making up the PolarCap® System. PolarCool at present is in close discussions with an Australian-based distributor, who will act as the company's sales and marketing arm in the country.

PolarCool CEO Erik Andersson comments:

-The entry into the Australian market is a significant milestone for PolarCools expansion as well as reaching our short-term goal to be profitable. We see a critical need for acute concussion treatment for athletes suffering concussions in Australia. We are excited to finalize our relationship with the distributor and start market establishment in this attractive market.

The Australian sports market is of particular interest for PolarCool due to the prevalence of contact sports played in the country. Australia has a strong sporting culture, with contact sports such as Rugby Union, Rugby League and Australian Rules Football, being highly popular. These sports have a high incidence of head injuries and concussions, where treatment with the PolarCap® System could be of great benefit for players suffering concussions.

This information is information that PolarCool (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on June 13[th], 2024.